Read our latest updates & insights

Bio-Thera announces BAT1706 (bevacizumab candidate) met the primary endpoint in Ph III clinical trials.

On 31 Jan 2020 Pfizer announced it had received a positive CHMP opinion for Ruxience® (biosimilar rituximab) in EU.

Pfizer announces positive CHMP opinion for Ruxience® .

Health Canada approves ulcerative colitis as an additional indication for Stelara®.

Significant biosimilar activities this week include
Jan 20 | Genentech and Roche commenced recruitment for Ph III clinical trials of their ranibizumab Port Delivery System (PDS) in patients with diabetic macular edema. The PDS uses a refillable eye implant to release ...

Pfizer launches Ruxience® in the US at a 24% discount to Rituxan®.

Pfizer announces biosimilar TmAb Trazimera® will launch in the US on 15 February at a 22% discount to Herceptin.

The UK’s NICE announces it will not recommend Stelara® for moderately to severely active ulcerative colitis due to uncertainties over cost-effectiveness.

AbbVie management acknowledge losses will be felt when biosimilar adalimumab products launch in the US market in 2023. Drawing from an international profit erosion of 45-48% for Humira® in 2019, AbbVie’s CEO Gonzalez warned stakeholders that biosimilar competition in ...

We previously reported that Fresenius Kabi surrendered its patent AU2015263246 in the patent office in November 2019, which was the subject of a revocation suit commenced by Samsung Bioepis in July 2019.  The Court entered orders today dismissing the proceeding by consent, ...